epoetin alfa

Generic Name: epoetin alfa

Clinical Trials

Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

Phase 2

Completed

Conditions: Anemia in End Stage Renal Disease

Interventions: Drug: FG-4592
Drug: Epoetin Alfa

First Posted Date: 2012-05-11

Last Posted Date: 2013-02-04

Lead Sponsor: FibroGen

Target Recruit Count: 96

Registration Number: NCT01596855

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
Chang Zheng Hospital, Shanghai, China
🇨🇳
RuiJin Hospital, Shanghai, China

and more 6 locations

Efficacy Study of Epoetin Alfa in Friedreich Ataxia

Phase 2

Completed

Conditions: Friedreich Ataxia

Interventions: Drug: Epoetin alfa
Drug: Placebo

First Posted Date: 2011-12-16

Last Posted Date: 2015-08-11

Lead Sponsor: Federico II University

Target Recruit Count: 56

Registration Number: NCT01493973

Locations: 🇮🇹
Università la Sapienza, Neurologia C, Rome, RM, Italy
🇮🇹
Dipartimento di Scienze Neurologiche, Napoli, Italy
🇮🇹
Università di Bari, Bari, BA, Italy

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation

Not Applicable

Terminated

Conditions: Anemia

Interventions: Drug: Epoetin Alfa

First Posted Date: 2011-02-07

Last Posted Date: 2014-02-27

Lead Sponsor: Mehrotra, Anita, M.D.

Target Recruit Count: 100

Registration Number: NCT01290328

Locations: 🇺🇸
Mount Sinai Medical Center, New York, New York, United States

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

Phase 2

Completed

Conditions: Anemia
End Stage Renal Disease

Interventions: Drug: Epoetin Alfa
Drug: Roxadustat
Other: Placebo

First Posted Date: 2010-06-22

Last Posted Date: 2022-01-11

Lead Sponsor: FibroGen

Target Recruit Count: 161

Registration Number: NCT01147666

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: LBH589
Drug: Epoetin Alfa

First Posted Date: 2009-12-17

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT01034657

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Erythropoietin in Traumatic Brain Injury (EPO-TBI)

Phase 3

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Epoetin Alfa
Drug: Sodium Chloride 0.9%

First Posted Date: 2009-10-01

Last Posted Date: 2016-07-26

Lead Sponsor: Australian and New Zealand Intensive Care Research Centre

Target Recruit Count: 606

Registration Number: NCT00987454

Locations: 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 25 locations

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Not Applicable

Withdrawn

Conditions: Anemia

Interventions: Drug: Epoetin alfa

First Posted Date: 2009-08-07

Last Posted Date: 2016-03-24

Lead Sponsor: Stanford University

Registration Number: NCT00954486

Locations: 🇺🇸
VAPAHCS, Palo Alto, California, United States
🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase 3

Active, not recruiting

Conditions: Anemia
Chronic Myelomonocytic Leukemia
De Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome

Interventions: Procedure: Bone Marrow Biopsy
Biological: Epoetin Alfa
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2009-02-13

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 247

Registration Number: NCT00843882

Locations: 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸
Saint Luke's Regional Medical Center, Sioux City, Iowa, United States
🇺🇸
Bozeman Health Deaconess Hospital, Bozeman, Montana, United States

and more 502 locations

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Phase 4

Completed

Conditions: Chronic Renal Anemia

Interventions: Drug: Darbepoetin Alfa
Drug: Epoetin Alfa
Drug: Epoetin Beta
Drug: methoxy polyethylene glycol-epoetin beta

First Posted Date: 2008-10-16

Last Posted Date: 2019-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2825

Registration Number: NCT00773513

Locations: 🇦🇺
Gosford Hospital; Renal, Gosford, New South Wales, Australia
🇭🇷
General Hospital Josip Bencevic; Department of Haemodialysis, Slavonski Brod, Croatia
🇦🇺
Renal Research Dr Simon Roger, Gosford, New South Wales, Australia

and more 193 locations

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Phase 3

Terminated

Conditions: Myelodysplastic Syndromes
Anemia

Interventions: Drug: Epoetin alfa
Drug: Placebo

First Posted Date: 2008-06-11

Last Posted Date: 2012-10-05

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 25

Registration Number: NCT00695396

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy